Released on October 10, 2017

Purpose:  To assess the safety of the superoxide mimetic GC4419 in combination with radiation and concurrent cisplatin for patients with oral cavity or oropharyngeal cancer (OCC) and to assess the potential of GC4419 to reduce severe oral mucositis (OM). Patients and Methods: ...

Released on August 08, 2017

Context: Despite numerous proposed mechanisms, no definitive pathophysiology underlying radiotherapy-induced fatigue (RIF) has been established.  However, the dysregulation of a set of 35 genes was recently validated to predict development of fatigue in prostate cancer patients receiving...

Released on June 08, 2017

Mucositis is a common complication of chemotherapy, radiotherapy and targeted agents.  It often affects compliance to anticancer therapies as it frequently causes schedule delays, interruptions or discontinuations of treatment.  Moreover, the economic impact related to the management...

Released on June 08, 2017

Anti-cancer agents that inhibit the mTOR pathway are associated with a number of unique toxicities, with one of the most significant and potentially dose-limiting being stomatitis. The objective of this study was to report the clinical features and management outcomes of a series of cancer...

Released on June 08, 2017

Of the toxicities associated with conventional forms of treatment for head and neck cancers, probably none has such a consistent legacy as oral mucositis.1 Despite the fact that mucosal injury was noted as far back as Marie Curie’s first forays into therapeutic radiation, an effective...

Released on June 08, 2017

Fatigue is a debilitating and pervasive complication of cancer and cancer care. Clinical research investigating potential therapies is hindered by variability in patient histories, different metrics for measuring fatigue, and environmental factors that may affect fatigue. The purpose of this...

Released on June 08, 2017

Background: Oral mucositis (OM) is a significant toxicity of induction chemotherapy for locally advanced head and neck cancer (LAHNC). The safety and tolerability of AG013, an oral rinse containing recombinant Lactococcus lactis secreting mucosal protectant human trefoil factor 1 (hTFF1), was...

Released on May 17, 2017

Innate immunity is a key component in the pathogenesis of oral mucositis, a universal toxicity of chemoradiation therapy (CRT).  Dusquetide, a novel Innate Defense Regulator, has demonstrated both nonclinical and clinical efficacy in ameliorating severe oral mucositis (SOM).  Long term...

Released on April 01, 2017

Oral mucositis remains one of the most dominant, serious, disruptive, and symptomatic complications of radiation therapy used for the treatment of cancers of the head and neck (Villa and Sonis, 2015).  Progressive mucosal injury accompanies increasing daily radiation fractions until...

Released on April 01, 2017

Objectives: Dacomitinib is a pan-HER inhibitor for advanced non-small-cell lung cancer (NSCLC).  We explored the impact of a planned 4-day dacomitinib dose interruption on plasma exposure of dacomitinib and adverse events (AEs) of interest in Cohort III of the ARCHER 1042 study. Materials...